CASES NOTIFICATION

EPIDEMIOLOGICAL SURVEILLANCE GROUP IN HISTOPLASMOSIS
[QUESTIONNAIRE PER PATIENT]

Back

Reg. No.
Date:
Responsable physician:
Laboratory:
Institutional Affiliation:
Institution:
Ciudad:
País:
 

PATIENT DATA

Name:
Sex:
M F
Age:
Status:
Phone:
Schooling:
Occupation:
Period: (occupation)
Address:
County:
State:
 
GEOGRAPHIC INDICATORS
State/country of origin:
State/country of residence:
State/last 5 years residence:

Residence:
USA, Canada Period:
Central America, South America Period:
 
ANTECEDENTS
Have you been tested for HIV When: %CD4: CD4/mm3:
Your partner When: %CD4: CD4/mm3:
 
PERSONAL DATA
Alcoholism:
Drugs:
Immunizations:
Allergy:

Corticosteroid therapy

Reason:
 
OCCUPATIONAL RISKS
Bat guano contact
      Reason: Period:
Bird guano contact
      Reason: Period:
Have you visited caves/mines/abandoned buildings?
      Reason: Period:
Do you work with any fungus?
      Reason: Period: Fungus:
 
PREVIOUS OR ASSOCIATED PATHOLOGIES
Cardiopathies
Coagulopaties
Enfermedades renales
Transplants
Cancer
Anemia
Diabetes mellitus
Leprosy
Tuberculosis
Other bacterial infections
Malaria
Toxoplasmosis
Previous pulmonary diseases
 
SIGNS AND SYMPTOMS IN THE LAST SIX MONTHS
Cough
Dyspnea
Weight loss about 10%
Chronic diarrhea
Diaphoresis
Asthenia/adynamia
Odynophagia
Hepato/splenomegaly
 Fever: Continued Vespertina without fever
 
CLINICAL DIAGNOSIS
Clinical manifestations:

Course:
New case
Endogenous reinfection
Exogenous reinfection
 
LABORATORY
Culture:
Histopathology:
Direct observation:
 
RADIOLOGY
Date:
Observations:
 
HUMORAL TESTS
Antibodies detected in: Serum
SF
Tests:   
PT
ID
CF   
ELISA
Antigens detected in: Serum
SF  
Urine
Tests:   
PT  
ID  
CF   
ELISA
 
CELLULAR TESTS
                   Histo/PPD
ST:    24h / mm
           48h / mm
           72h / mm
                      Histo/PPD
LT:    Ag       / mm
         PHA     / mm
         Con A  / mm
 
HLA
Class I:
Class II:
Class III:
 
OPHTALMOLOGICAL EVALUATION
Previous ocular diseases:
Medicines:
Period:
Ametropia Ocular fundus exploration:
Ophtalmologic clinical studies:
Comments:

       

Back